Vector co-expressing vaccine and costimulatory molecules

Abstract

Compositions and methods for co-expressing a secretable vaccine protein (such as gp96-Ig) and T-cell co-stimulatory molecules from a single vector, among others, are provided herein. Materials and methods for using gp96-Ig vaccination and T-cell co-stimulation to treat a clinical condition (e.g., cancer) in a subject also are provided.

1 . An expression vector comprising a first nucleotide sequence that encodes a secretable vaccine protein, and a second nucleotide sequence that encodes a T cell costimulatory fusion protein comprising TL1A-Ig, wherein the TL1A-Ig protein comprises an amino acid sequence having at least 97% to SEQ ID NO: 9 and enhances activation of antigen-specific T cells when administered to a subject. 
     
     
         2 . The expression vector of  claim 1 , wherein the vector is a mammalian expression vector. 
     
     
         3 . The expression vector of  claim 1 , wherein the secretable vaccine protein is a gp96-Ig fusion protein that lacks the gp96 KDEL (SEQ ID NO:3) sequence. 
     
     
         4 . The expression vector of  claim 3 , wherein the Ig tag in the gp96-Ig fusion protein comprises the Fc region of human IgG1, IgG2, IgG3, or IgG4. 
     
     
         5 - 12 . (canceled) 
     
     
         13 . The expression vector of  claim 1 , wherein the expression vector comprises DNA. 
     
     
         14 . The expression vector of  claim 1 , wherein the expression vector comprises RNA. 
     
     
         15 - 26 . (canceled) 
     
     
         27 . The expression vector of  claim 1 , wherein the expression vector is incorporated into a virus or virus-like particle. 
     
     
         28 . The expression vector of  claim 1 , wherein the expression vector is incorporated into a human tumor cell. 
     
     
         29 . The expression vector of  claim 28 , wherein the human tumor cell is a cell from an established non-small cell lung carcinoma (NSCLC), bladder cancer, melanoma, ovarian cancer, renal cell carcinoma, prostate carcinoma, sarcoma, breast carcinoma, squamous cell carcinoma, head and neck carcinoma, hepatocellular carcinoma, pancreatic carcinoma, or colon carcinoma cell line. 
     
     
         30 - 42 . (canceled) 
     
     
         43 . The expression vector of  claim 1 , wherein the secretable vaccine protein is a gp96-Ig fusion protein comprising gp96 that includes the first 799 amino acids of SEQ ID NO: 2, such that the gp96-Ig fusion protein lacks a C-terminal KDEL (SEQ ID NO: 3) sequence. 
     
     
         44 . The expression vector of  claim 43 , wherein the Ig tag of the gp96-Ig fusion protein comprises CH2 and CH3 domains of a human IgG. 
     
     
         45 . The expression vector of  claim 44 , wherein the human IgG is human IgG1. 
     
     
         46 . A human tumor cell comprising the expression vector of  claim 1 .